GlassScriptPhysician profile
Davene Wells
NPI 1386033645
$7,740.48
in general payments reported to CMS, 2019-2025
24 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,848 · 2022: $2,904 · 2023: $1,348 · 2024: $1,084 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,987.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,994.49 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Abbvie INC. | $1,234.60 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $769.52 | 2021-2025 | Relistor |
| Nevro Corp. | $461.62 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $365.51 | 2021-2025 | Ztlido |
| Medtronic, INC. | $334.06 | 2021-2022 | |
| Grt US Holding, INC. | $309.99 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $283.50 | 2021 | |
| Protega Pharmaceutials INC | $239.74 | 2023-2024 | Roxybond |
| Curonix LLC | $236.05 | 2022-2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stimwave Technologies Incorporated | $225.40 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $208.07 | 2021-2025 | Belbuca, Xtampza |
| Biohaven Pharmaceutical Holding Company LTD. | $200.44 | 2022 | |
| Nalu Medical, INC. | $192.95 | 2022-2023 | Nalu Neurostimulation System |
| Averitas Pharma INC. | $158.84 | 2023-2024 | Qutenza |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $146.30 | 2021 | |
| Pfizer INC. | $108.33 | 2023 | |
| Lilly USA, LLC | $71.05 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $69.08 | 2024-2025 | |
| Tersera Therapeutics LLC | $36.81 | 2022 | |
| Pacira Therapeutics, INC. | $28.53 | 2021 | |
| Vertos Medical, INC. | $25.72 | 2023 | Mild Device Kit |
| Almatica Pharma LLC | $22.32 | 2021 | |
| Novo Nordisk INC | $17.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Davene Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.